News for Intra-Cellular Therapies, Inc. (ITCI)

Merck & Co., Inc. (MRK) acquired Verona Pharma plc (VRNA) for $10 billion, boosting Verona’s shares by over 20% to $104.77, with the deal centered on Verona’s first-in-class COPD drug Ohtuvayre. Ohtuvayre, a novel inhaled therapy approved 13 months ago, generated $71.3 million in Q1 2025 sales with 95% sequential…

On May 27, 2025, GLAZER CAPITAL, LLC (Trades, Portfolio) executed a notable transaction by acquiring 22,614,623 shares of E2open Parent Holdings Inc (ETWO) at a

On May 23, 2025, GLAZER CAPITAL, LLC (Trades, Portfolio) made a notable move in the stock market by acquiring 3,489,541 shares of PHX Minerals Inc. This transac

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases. Blueprint Medicines shares were trading more than 26% higher ahead of US market open.

Exploring the Strategic Portfolio Adjustments in Q1 2025 Paul Tudor Jones (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025,

Exploring the Latest 13F Filing and Investment Strategies John Paulson (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, pro

Insight into Gabelli's First Quarter 2025 Portfolio Adjustments Mario Gabelli (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 20

On March 17, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a noteworthy transaction by acquiring 2,357,702 shares of Dianthus Therapeutics Inc at a

On March 4, 2025, Suvretta Capital Management, LLC executed a strategic acquisition of 4,727,510 shares in Aadi Bioscience Inc, a company specializing in precli

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc.

Although biotech stocks had a

China's stock market outperforms US as AI investments and shifting sentiment drive surge in tech stocks. Citi and Goldman Sachs revise ratings.

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.

The worst enemy of a booming market for mergers and acquisitions has always been uncertainty. That’s a problem for dealmakers, who were expecting a banner year unde…

Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses. This March, I plan to buy several, including PepsiCo (NASDAQ: PEP), Johnson & Johnson (NYSE: JNJ), and Prologis (NYSE: PLD).

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc.

PR NewswireNEW YORK, Feb. 26, 2025 NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...